Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

  n = 107
Age, years (range) 63 (29–77)
Sex
 Male 60 (56%)
 Female 47 (44%)
Eastern Clinical Oncology Group (ECOG) paformance status
 0 93 (87%)
 1 14 (13%)
Main location of the tumor
 Rectosigmoid 5 (5%)
 Upper rectum 54 (50%)
 Lower rectum 48 (45%)
Surgical approach
 Laparoscopic 77 (72%)
 Open 30 (28%)
Surgical procedure
 HAR 10 (9%)
 LAR 79 (74%)
 ISR 4 (4%)
 Hartmann’s procedure 2 (2%)
 APR 12 (11%)
 Lateral lymph node dissection by the main location of the tumor 19 (18%)
 Upper rectum 3
 Lower rectum 16
 Operation time, minutes (range) 311 (122–914)
 Intraopelative bleeding, ml (range) 45 (0–2100)
 Stoma creation 47 (44%)
 Postoperative complications 18 (17%)
Histology
 pap/tub1/tub2 1/33/71
 por1/por2/muc/sig 1/1/0/0
Pathological T category
 T1 7 (7%)
 T2 19 (18%)
 T3 66 (62%)
 T4a 12 (11%)
 T4b 3 (3%)
Pathological N category
 N0 8 (8%)
 N1a 24 (22%)
 N1b 29 (27%)
 N2a 21 (20%)
 N2b 25 (23%)
Pathological stage
 IIA 5 (5%)
 IIB 3 (3%)
 IIIA 17 (16%)
 IIIB 57 (53%)
 IIIC 25 (23%)
  1. HAR high anterior resection, LAR low anterior resection, ISR intersphincteric resection, APR abdominoperineal resection